Uni- and Multivariate Analyses for Potential Factors Associated with Time to Progression of BMs
| Progression-free survival | Univariate analysis | Multivariate analysis | ||||||
| Variable | Median (mo) | 95% CI | HR | 95% CI | P | HR | 95% CI | P |
| Total | 35 | 26–44 | ||||||
| Age | ||||||||
| ≤65 y | 35 | 16–54 | ||||||
| >65 y | 29 | 19–39 | — | 0.823 | ||||
| Tumor type | ||||||||
| Pancreatic NET | 29 | 18–40 | — | 0.497 | ||||
| Other GEP NETs | 35 | 16–54 | ||||||
| Performance status | ||||||||
| Karnofsky performance score ≤ 70 | 29 | 18–40 | — | 0.629 | ||||
| Karnofsky performance score > 70 | 35 | 26–44 | ||||||
| Chromogranin A | ||||||||
| ≤600 ng/mL | 42 | 31–53 | ||||||
| >600 ng/mL | 24 | 12–36 | 3.2 | 1.1–9.5 | 0.039 | 2.1 | 0.6–7.6 | 0.245 |
| Neuron-specific enolase | ||||||||
| ≤15 ng/mL | 35 | 8–62 | ||||||
| >15 ng/mL | 31 | 25–37 | — | 0.708 | ||||
| Ki-67 index | ||||||||
| ≤10% | 35 | 26–44 | ||||||
| >10% | 15 | 6–24 | 5.2 | 1.5–18.0 | 0.01 | 3.4 | 0.9–13.7 | 0.083 |
| No. of lesions | ||||||||
| Few (≤10) | 31 | 19–43 | ||||||
| Multiple | 35 | 19–51 | — | 0.773 | ||||
| Tracer uptake | ||||||||
| ≤Grade 2 | 42 | 23–61 | ||||||
| >Grade 2 | 29 | 22–36 | — | 0.314 | ||||